At a glance
ClinicalIndex Comparison Record- ✓Newly diagnosed, pathologically confirmed FIGO stage III or IV ovarian cancer
- ✓High grade serous, high grade endometrioid, or other epithelial ovarian cancer with BRCA1/2 deleterious alteration
- ✓Ovarian, fallopian, or primary peritoneal cancer
- ✓BRCA1/2 pathogenic/suspected pathogenic variant (germline or somatic)
- ✕Previous PARP inhibitor treatment (olaparib, niraparib, rucaparib)
- ✕Active infection requiring parenteral antibiotics
- ✕Intra-abdominal abscess, abdominal/pelvic fistula, GI perforation, GI obstruction, or need for NG/gastrostomy tube
- ✕Unable to swallow oral medication
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
In Brief
A Phase 3 clinical trial evaluating Bevacizumab, Biospecimen Collection, and 3 other interventions for Fallopian Tube Endometrioid Adenocarcinoma and 8 related conditions. Currently recruiting, targeting 880 participants across 676 sites in 3 countries.
Signals
Detailed Summary
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Study Details
Timeline
Interventions
Given IV
Undergo blood sample collection
Undergo CT
Undergo MRI
Given PO